Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.
Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.